These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26181154)

  • 1. [Secondary hyperparathyroidism--treatment review].
    Graczyk M
    Wiad Lek; 2015; 68(2):179-82. PubMed ID: 26181154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in pharmacotherapy for secondary hyperparathyroidism.
    Rodríguez M; Rodríguez-Ortiz ME
    Expert Opin Pharmacother; 2015; 16(11):1703-16. PubMed ID: 26159447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
    Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
    G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
    Rodríguez M; Goodman WG; Liakopoulos V; Messa P; Wiecek A; Cunningham J
    Semin Dial; 2015; 28(5):497-507. PubMed ID: 25752650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.
    Fukagawa M; Komaba H; Kakuta T
    Expert Opin Pharmacother; 2013 May; 14(7):863-71. PubMed ID: 23521343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
    Cunningham J; Locatelli F; Rodriguez M
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):913-21. PubMed ID: 21454719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroidectomy in the Management of Secondary Hyperparathyroidism.
    Lau WL; Obi Y; Kalantar-Zadeh K
    Clin J Am Soc Nephrol; 2018 Jun; 13(6):952-961. PubMed ID: 29523679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
    Hudson JQ
    Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy of chronic kidney disease and mineral bone disorder.
    Barreto FC; de Oliveira RA; Oliveira RB; Jorgetti V
    Expert Opin Pharmacother; 2011 Dec; 12(17):2627-40. PubMed ID: 22017388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience].
    Pulvirenti D; Aikaterini T; Campagna A; Ignaccolo L; Giustolisi N; Costa E
    Clin Ter; 2008; 159(5):307-10. PubMed ID: 18998031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of parathyroidectomy versus calcimimetics for secondary hyperparathyroidism and kidney transplantation: a propensity-matched analysis.
    Koh EY; van der Plas WY; Dulfer RR; Pol RA; Kruijff S; Rotmans JI; Appelman-Dijkstra N; Schepers A; de Borst MH; Hoorn EJ; van Ginhoven TM; Nieveen van Dijkum EJM; Vogt L; Engelsman AF;
    Langenbecks Arch Surg; 2020 Sep; 405(6):851-859. PubMed ID: 32778916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?
    Brown AJ
    J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):578-83. PubMed ID: 17368185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Indications for parathyroidectomy in renal hyperparathyroidism: comments on the significance of new therapeutics].
    Dotzenrath C
    Chirurg; 2010 Oct; 81(10):902-8. PubMed ID: 20683565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ; Slatopolsky E
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges.
    Komaba H; Shiizaki K; Fukagawa M
    Expert Opin Biol Ther; 2010 Dec; 10(12):1729-42. PubMed ID: 21058933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of secondary hyperparathyroidism in Italy: results of the Italian FARO survey.
    Mazzaferro S; Brancaccio D; Messa P; Andreucci VE; Bellinghieri G; Bigazzi R; Bolasco P; Costanzo AM; di Luzio Paparatti U; Cannella G;
    J Nephrol; 2011; 24(2):225-35. PubMed ID: 21188680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.